NgoDisemba 2007, uNks. 54, owayekhulise i-hemoptysis izinyanga ezimbili, wehla isisindo, walahlekelwa ukudla, waba nobuhlungu bamathambo. A Ukuhlolwa kwesifuba se-CT iveze i-9 cm x 5.8 cm x 7.2 cm "enkulu, enamanzi amaningi, ethuthukisiwe ngokungafani" engxenyeni engezansi engakwesokunxele yamaphaphu. Ngaphezu kwalokho, kwatholakala esinye isilonda esincane esifana nenaliti engxenyeni ephezulu yesobunxele.
Kamuva, i-biopsy yaqinisekisa ukuthi ihlasele, yahlukanisa ngokulinganisela i-lung squamous cell carcinoma. A CT scan showed involvement of the chest wall muscles and had metastasized. Her bone scan was negative (no metastases). Therefore, she was diagnosed with T4N1M0-IIIb stage non-small cell umdlavuza wamaphaphu.
Ezinyangeni ezingu-3, uNksz M welashwa nge-paclitaxel (260 mg) ne-carboplatin (415 mg) imijikelezo engu-3. Lokhu kunciphisa isisu kuya ku-7 x 6 cm x 5 cm. Kamuva, i-chemoradiotherapy yenziwa ngokuhambisana nemijikelezo emi-2 ye-cisplatin (50 mg) kanye ne-60 Gy yemisebe.
Ezinyangeni ezimbili ngemuva kokuphothulwa kwe-chemoradiotherapy, uNksz M wathola ukuthi kwakukhona ukuhlolwa komtholampilo kwephaphu. umuthi wokugomela umdlavuza and decided to receive CIMAvax vaccine after thinking about it.
Abantu abangama-80% abathole ukwelashwa kwe-cyclophosphamide ngaphambi komjovo we-CIMAvax bakhombise umsebenzi othile olwa ne-EGF. Ukugoma ezindaweni eziningi kuzothuthukisa nokusebenza.
I-CT scan yangaphambi kokuhlinzwa ibonise isilonda esingu-3 cm x 3 cm ku-lobe engezansi (Umfanekiso 1). Izilonda ze-lobe engenhla kwesokunxele zazingaphansi kuka-1 cm ububanzi, futhi ukukhishwa kwe-pleural kwasendaweni kwakungokwesibili ku-radiotherapy.
Ngemuva kwezinyanga ezintathu zokulashwa komuthi wokugomela umdlavuza wamaphaphu we-CIMAvax, isimila sinciphe safinyelela ku-3 cm x 2 cm
Ngezinyanga eziyisithupha zokwelashwa, isimila sase sinciphile kusuka kumthamo waso wokuqala ngo-6% kuya ku-30 cm x 1.5 cm ngaphambi kokuqiniswa. Ngalesi sikhathi, ukukhishwa kwakhe kokuncenga okuqhubekayo kwancipha, futhi ama-lymph node asendaweni aba mancane.
Ngesikhathi sokudubula okungu-16 kokuqala, uNks M akazange abhekane neminye imiphumela emibi. Akuphelanga mizuzu emincane ngomjovo we-17, izinhlungu zakhe okhalweni zase "zikhuphukile" futhi kwathathwa njengempendulo ehlobene nokugoma yeBanga lesi-3. Izimpawu zinciphile ngemuva kwemizuzu eyi-10 yokwelashwa nge-10 mg ye-chlorpheniramine, i-200 mg ye-hydrocortisone kanye ne-50 mg ye-tramadol.
Kamuva, wanquma ukuyeka ukwelashwa ngomuthi wokugomela we-CIMAvax. Iskena se-CT esifubeni senziwa ezinyangeni ezintathu ngemuva kokuyeka ukwelashwa (izinyanga eziyi-18 ngemuva kokuqala ukwelashwa kwe-CIMAvax). Sekudlule izinyanga eziyisithupha selokhu ahlolwa okokugcina, futhi alukho “ushintsho olukhulu” ngosayizi wesimila (Umfanekiso 3), futhi isimo sakhe sihlale sizinzile.
Ezinyangeni zokugcina ezingama-28 ngemuva kokumisa ukugoma i-FNM yabesifazane yayisesimweni esihle futhi iphilile futhi izinzile. Isimo sakhe se-ECOG sihlale ku-0 (okuhle kakhulu). Kuleli qophelo, usesindile ezinyangeni ezingama-48 selokhu axilongwa kanti isimo sakhe sisalokhu sizinzile.
Ms. M ’s umuthi wokugomela umdlavuza wamaphaphu was approved for marketing in Cuba in 2008 for maintenance treatment of stage IIIB-IV non-surgical advanced non-small cell lung cancer (NSCLC). This is the first registration of a therapeutic vaccine in Cuba and the first registration of a lung cancer vaccine in the world.
